Approaches for Systemic Delivery of Dystrophin Antisense Peptide Nucleic Acid in the mdx Mouse Model.

Nucleic Acid Therapeutics
Camilla BrolinPeter E Nielsen

Abstract

Antisense-mediated exon skipping constitutes a promising new modality for treatment of Duchenne Muscular Dystrophy (DMD), which is caused by gene mutations that typically introduce a translation stop codon in the dystrophin gene, thereby abolishing production of functional dystrophin protein. The exon removal can restore translation to produce a shortened, but still partially functional dystrophin protein. Peptide nucleic acid (PNA) as a potential antisense drug has previously been shown to restore the expression of functional dystrophin by splice modulation in the mdx mouse model of DMD. In this study, we compare systemic administration of a 20-mer splice switching antisense PNA oligomer through intravenous (i.v.) and subcutaneous (s.c.) routes in the mdx mice. Furthermore, the effect of in situ forming depot technology (BEPO®) and PNA-oligonucleotide formulation was studied. In vivo fluorescence imaging analysis showed fast renal/bladder excretion of the PNA (t½ ∼ 20 min) for i.v. administration, while s.c. administration showed a two to three times slower excretion. The release from the BEPO depot exhibited biphasic kinetics with a slow release (t½ ∼ 10 days) of 50% of the dose. In all cases, some accumulation in kidneys and...Continue Reading

References

May 1, 1995·Journal of Peptide Science : an Official Publication of the European Peptide Society·L ChristensenR H Berg
Jun 21, 2002·Antisense & Nucleic Acid Drug Development·Beth M McMahonElliott Richelson
Nov 12, 2002·Nature Biotechnology·Peter SazaniRyszard Kole
Oct 31, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Haifang YinMatthew Wood
Jan 14, 2009·Molecular Cancer Therapeutics·Mikako OgawaHisataka Kobayashi
Jan 14, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·HaiFang YinMatthew J A Wood
Apr 10, 2012·Molecular Pharmaceutics·Christopher J Cheng, W Mark Saltzman
Jun 12, 2012·Proceedings of the National Academy of Sciences of the United States of America·Imran A BabarFrank J Slack
Nov 20, 2014·Nature·Christopher J ChengFrank J Slack
Jun 13, 2018·Molecular Cancer Therapeutics·Wilhem LeconetNeil H Bander
Sep 22, 2019·Current Opinion in Chemical Biology·Jacques SaarbachNicolas Winssinger
Jan 14, 2020·Journal of Controlled Release : Official Journal of the Controlled Release Society·Christophe RobergeAdolfo Lopez-Noriega

❮ Previous
Next ❯

Citations

Aug 10, 2021·Beilstein Journal of Organic Chemistry·Nikita BrodyaginEriks Rozners

❮ Previous
Next ❯

Methods Mentioned

BETA
transgenic
PCR
fluorescence imaging

Software Mentioned

NIS Elements
GraphPad Prism
Living Image

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.